Kineret is a recombinant version of the naturally occurring IL-1 receptor antagonist (IL-1Ra). Kineret acts by competitively inhibiting the biological activity of interleukin- 1α (IL-1α) and interleukin-1β (IL-1β), preventing both cytokines from attaching to the IL-1 receptor (IL-1R1) and initiating downstream signalling cascades.1,2 By blocking the interaction between IL-1α/IL-1β and IL-1R1, Kineret interrupts IL- 1-mediated inflammatory processes and alleviates the signs and symptoms of conditions characterised by excessive or dysregulated IL-1 responses.2
Kineret neutralises the biologic activity of IL-1α and IL-1β by competitively inhibiting their binding to IL-1R1.1
Kineret has high absolute bioavailability after subcutaneous administration; maximum plasma concentrations are reached within 3 to 7 hours and the terminal elimination half-life is 4 to 6 hours. Kineret induces a rapid resolution of systemic features such as fever, rash, and elevation of acute phase reactants.1
Please refer to current SmPC for more information about the safety and efficacy of Kineret.